研究者詳細 - 寺井　崇二

論文 - 寺井　崇二

分割表示 1,104 件中 441 - 460 件目／全件表示 >>

肝癌分子標的薬治療時の鰹だし併用による肝予備能維持効果

小関洋平, 上村顕也, 坂牧僚, 大越麻理奈, 田中裕登, 寺井崇二

日本消化器病学会雑誌 117 ( 臨増総会 ) A296 - A296 2020年7月

臨床応用に向けた肝癌の病態解明放射線照射によるDNA損傷時のHHMの役割

丹羽佑輔, 上村顕也, 寺井崇二

日本消化器病学会雑誌 117 ( 臨増総会 ) A161 - A161 2020年7月

Cytapheresis for pyoderma gangrenosum associated with inflammatory bowel disease: A review of current status. 査読国際誌

Kentaro Tominaga, Kenya Kamimura, Hiroki Sato, Masayoshi Ko, Yuzo Kawata, Takeshi Mizusawa, Junji Yokoyama, Shuji Terai

World journal of clinical cases 8 ( 11 ) 2092 - 2101 2020年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

Pyoderma gangrenosum (PG) is a neutrophilic dermatosis clinically characterized by the presence of painful skin ulcerations with erythematous. As it is frequently associated with inflammatory bowel diseases, including ulcerative colitis, gastroenterologists should be familiar with the disease including therapeutic options. Therefore, we have conducted a review focusing on the cytapheresis for PG in cases of inflammatory bowel diseases. A literature search was conducted to extract studies published in the last 20 years, with information on demographics, clinical symptoms, treatment, and the clinical course from a total of 22 cases reported and our recent case. In most patients, cytapheresis was associated with improvement or resolution of PG after failure of conventional therapeutic options such as corticosteroids, antibiotics, immunosuppressive agents and immunoglobulin. Based on the information summarized, cytapheresis is helpful in the majority of patients with PG refractory to medical treatment associated with inflammatory bowel diseases and could be further studied in a multicenter, randomized trial.

DOI： 10.12998/wjcc.v8.i11.2092

PubMed

researchmap

Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles. 査読国際誌

Takayuki Watanabe, Atsunori Tsuchiya, Suguru Takeuchi, Shunsuke Nojiri, Tomoaki Yoshida, Masahiro Ogawa, Michiko Itoh, Masaaki Takamura, Takayoshi Suganami, Yoshihiro Ogawa, Shuji Terai

Regenerative therapy 14 252 - 261 2020年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

Introduction: Currently, there are no approved drugs for treating non-alcoholic steatohepatitis (NASH); however, mesenchymal stem cells (MSCs) and their small extracellular vesicles (sEVs), which possess immunomodulatory activities, are potential candidates. This study aimed to develop a mouse model of NASH with rapid accumulation of fibrosis using the pre-established melanocortin type-4 receptor knockout (Mc4r-KO) NASH mouse model and lipopolysaccharide (LPS), and to evaluate the therapeutic effect of MSCs and their sEVs. Methods: Mc4r-KO mice (8 weeks old, male) were fed a western diet (WD) for 8 weeks. Next, the mice were intraperitoneally injected with lipopolysaccharide (LPS) twice a week for 4 weeks while continuing the WD. To confirm the therapeutic effect of MSCs and sEVs, human adipose tissue-derived MSCs or their sEVs were administered 12 weeks after initiation of the WD, and serum testing, quantitative analysis of fibrosis, and quantitative reverse transcription-polymerase chain reaction qRT-PCR were performed. Results: By providing a WD combined with LPS treatment, we successfully developed a NASH model with rapid accumulation of fibrosis. Both human MSCs and their sEVs decreased serum alanine transaminase levels and inflammatory markers based on qRT-PCR. Histological analysis showed that MSC or sEV treatment did not affect fat accumulation. However, an improvement in fibrosis in the groups treated with MSCs and their sEVs was observed. Furthermore, after administering MSCs and sEVs, there was a significant increase in anti-inflammatory macrophages in the liver. Conclusion: We successfully developed a NASH model with rapid accumulation of fibrosis and confirmed the anti-inflammatory and anti-fibrotic effects of MSCs and their sEVs, which may be options for future therapy.

DOI： 10.1016/j.reth.2020.03.012

PubMed

researchmap

A rare case of peliosis hepatis in a patient with chronic renal failure and renal cell carcinoma.

Hiroki Maruyama, Kazuya Takahashi, Natsuki Ishikawa, Kazunori Hosaka, Daisuke Kumaki, Yukio Aruga, Masashi Yamakawa, Masaaki Hirano, Kazuhiro Funakoshi, Shuji Terai

Clinical journal of gastroenterology 13 ( 3 ) 403 - 407 2020年6月

記述言語：英語掲載種別：研究論文（学術雑誌）

Peliosis hepatis (PH) is a rare disease characterized by the presence of sinusoidal dilation and blood-filled cysts throughout the hepatic parenchyma. We report a case of PH in a 49-year-old woman with chronic renal failure (CRF) on hemodialysis and with renal cell carcinoma (RCC). Dynamic contrast-enhanced computed tomography (CT) showed a 35-mm-diameter, hypervascular tumor in the liver and RCC in the right renal cyst. Ultrasound and superparamagnetic iron oxide-enhanced magnetic resonance imaging were also performed; however, the liver tumor could not be distinguished from the metastasis of RCC. Therefore, echo-guided biopsy of the liver tumor using an 18-G Majima needle was performed. Histological evaluation of the specimen showed irregular sinusoidal dilatation and blood-filled cavities without malignant cells. She was ultimately diagnosed with PH. Subsequently, she underwent total right nephrectomy for RCC and was diagnosed with RCC stage 1 (pT1N0M0). A follow-up CT performed 4 months after nephrectomy showed no growth of PH. Although the development of PH in patients with CRF or RCC who do not undergo renal transplantation is extremely rare, it should be considered in the differential diagnosis to distinguish PH from the metastasis of RCC.

DOI： 10.1007/s12328-019-01068-5

PubMed

researchmap

【幹細胞治療と疾患】間葉系幹細胞は"指揮細胞"としてマクロファージに作用し肝硬変の肝線維化改善、再生を誘導する自己骨髄細胞投与療法から他家脂肪組織由来間葉系幹細胞投与へ

寺井崇二, 土屋淳紀

BIO Clinica 35 ( 5 ) 406 - 410 2020年5月

記述言語：日本語出版者・発行元：(株)北隆館

肝臓は再生能力の高い臓器として知られているが、肝障害が遷延し進行した肝硬変に進展するとその再生能力は落ち、現在根本的に改善する治療は肝移植である。しかし肝移植はドナーの不足という深刻な状態に直面している。現在、肝硬変の線維化改善、再生促進を目指した新規治療が世界中で開発を目指して展開されているが、細胞治療もその一つである。我々は2003年に肝硬変症に対する自己骨髄細胞投与療法の臨床研究を開始し、その過程において、肝線維化改善に伴う肝再生、肝機能の改善を明らかにしてきた。一方でさらに再生医療として考えた場合、今後は自己から他家細胞投与が必要と考えられた。基礎研究を踏まえ、2017年よりロート製薬と肝硬変症に対する他家脂肪由来間葉系幹細胞投与の治験を開始した。一方で、基礎研究の解析では間葉系幹細胞投与療法において、間葉系幹細胞は指揮細胞として作用し、マクロファージをM2型に変化させ、肝線維化改善、肝再生を誘導することも明らかになってきた。本稿では我々が現在までの他家間葉系幹細胞の臨床展開までの道のりを概説する。(著者抄録)

researchmap

Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis: A Case Report. 査読

Akira Sakamaki, Kunihiko Yokoyama, Fusako Yamazaki, Hiroteru Kamimura, Kenya Kamimura, Masaaki Takamura, Junji Yokoyama, Shuji Terai

Internal medicine (Tokyo, Japan) 59 ( 15 ) 1849 - 1853 2020年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

A 66-year-old Japanese man was admitted to our hospital with grade 2 hepatic encephalopathy (HE). Abdominal computed tomography and laboratory examinations revealed decompensated liver cirrhosis. Intravenous administration of branched-chain amino acids immediately ameliorated the HE, and lactulose was initiated. However, a breath test revealed small intestinal bacterial overgrowth (SIBO); therefore, rifaximin was additionally initiated. The breath test was repeated after discharge, when no evidence of SIBO or overt HE was identified. This case suggested that a breath test is effective for the identification of SIBO and that the administration of a poorly absorbed antibiotic should be considered in SIBO-positive HE patients taking lactulose.

DOI： 10.2169/internalmedicine.4593-20

PubMed

researchmap

Effect of methionine/choline-deficient diet and high-fat diet-induced steatohepatitis on mitochondrial homeostasis in mice. 査読国際誌

Yoshihisa Arao, Hirokazu Kawai, Kenya Kamimura, Takamasa Kobayashi, Oki Nakano, Manabu Hayatsu, Tatsuo Ushiki, Shuji Terai

Biochemical and biophysical research communications 527 ( 2 ) 365 - 371 2020年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

Considering the increase in cases of non-alcoholic steatohepatitis (NASH), the use of appropriate animal model of NASH is essential to understand the underlying pathogenesis mechanism. To date, several mice models have been used; however, significant differences in the etiologies and food administered affected the results, with inconsistent conclusions. Therefore, it is necessary to understand these models and their differences to be able to choose appropriate models. Inspired by the fact that mitochondrial (mt)DNA content is changed in non-alcoholic fatty liver disease in humans, we investigated the mtDNA copy number in the NASH mice models induced by high-fat diet (HFD) and methionine/choline-deficient diet (MCD) to understand the differences between these models. Megamitochondria were observed in both MCD and HFD groups. However, the MCD group showed significant decrease in liver mtDNA content compared with that in the HFD group. These changes were associated with significant upregulation of mitochondrial biogenesis- and degradation-related genes in MCD model than in HFD model. Thus, stability of mtDNA is associated with the differences between MCD and HFD-induced NASH models often used in studies; these findings could help in choosing appropriate models for studies on NASH.

DOI： 10.1016/j.bbrc.2020.03.180

PubMed

researchmap

Rare Genotype of His/His in NUDT15 Codon 139 and Thiopurine-associated Adverse Events in a Case of Ulcerative Colitis. 査読

Kei Tomiyoshi, Hiroki Sato, Kentaro Tominaga, Yuzo Kawata, Daisuke Okamoto, Yoichi Kakuta, Junji Yokoyama, Shuji Terai

Internal medicine (Tokyo, Japan) 59 ( 13 ) 1611 - 1613 2020年4月

記述言語：英語掲載種別：研究論文（学術雑誌）

Thiopurine drugs are commonly used to treat immunologic diseases. However, the narrow therapeutic safety margin demands evidence-based precision medicine approaches. NUDT15 variants are associated with thiopurine-induced adverse events, particularly in Asians. We herein report a rare genotype of His/His in NUDT15 codon 139 in a case of ulcerative colitis and review the relevant literature. The patient experienced severe thiopurine-associated adverse events, including leukopenia and alopecia. There is no literature on the His/His genotype in NUDT15 codon 139, and our case suggests cautious use or the contraindication of thiopurines for patients with this genotype.

DOI： 10.2169/internalmedicine.4261-19

PubMed

researchmap

新潟県における肝炎対策査読

荒生祥尚, 菊田玲, 渡辺和仁, 中山均, 田村務, 薛徹, 寺井崇二

肝臓 61 ( Suppl.1 ) A263 - A263 2020年4月

当院における肝炎医療コーディネーターの取り組みと今後の課題査読

廣川光, 薛徹, 荒生祥尚, 澤栗裕美, 寺井崇二

肝臓 61 ( Suppl.1 ) A246 - A246 2020年4月

Huge liver tumor in young man. 査読国際誌

Osamu Shibata, Kenya Kamimura, Rie Azumi, Kei Shibuya, Shintaro Shiba, Tatsuya Ohno, Shuji Terai

JGH open : an open access journal of gastroenterology and hepatology 4 ( 2 ) 301 - 302 2020年4月

記述言語：英語

Intrahepatic cholangiocarcinoma is the second leading primary hepatic tumors, accounting for 5% of all hepatic tumors. The curability depends on the operability; however, the difficulty of early diagnosis and late clinical presentation account for the poor prognosis. Therefore, development of a novel therapeutic option and a method to determine the viability of the primary tumor, which hinder the assessment of the impact of other therapies, including chemotherapy and radiotherapy are needed. Although FDG-PET has been used to detect distant metastases of ICC, which are present in 20% of patients at the initial diagnosis, little is known about the efficacy of FDG-PET of the primary lesion of ICC. Here, we present the case of a 31-year-old male diagnosed with unresectable ICC and successfully treated with carbon-ion radiation, and present the usefulness of fluorodeoxyglucose-positron emission tomography in the determination of the viability of the tumor.

DOI： 10.1002/jgh3.12234

PubMed

researchmap

Hypereosinophilia-related liver pseudotumor with elevated interleukin-5 levels preceding T-cell lymphoma. 国際誌

Atsunori Tsuchiya, Tomoyuki Tanaka, Yasuhiko Shibasaki, Shuji Terai

JGH open : an open access journal of gastroenterology and hepatology 4 ( 2 ) 312 - 314 2020年4月

記述言語：英語

A 61-year-old woman with hypereosinophilia and elevated interleukin (IL)-5 level was admitted to our hospital after detection of multiple liver tumors. Liver biopsy demonstrated that the tumor consisted of scar tissue with remnants of eosinophilic infiltration, suggesting that it had formed by massive eosinophilic infiltration. The hypereosinophilia was treated mainly by prednisolone, and thereafter, the liver tumors disappeared. However, 10 months postadmission, CD4+ T-cell lymphoma, which can produce IL-5, was detected in the nasopharynx and oropharynx. Therefore, we believe that this is a rare case of hypereosinophilia-related liver pseudotumor induced by presumed by IL-5 elevation.

DOI： 10.1002/jgh3.12253

PubMed

researchmap

自己免疫性肝炎における赤血球容量粒度分布幅変動係数の臨床的意義

高村昌昭, 高綱将史, 薛徹, 上村博輝, 土屋淳紀, 寺井崇二

肝臓 61 ( Suppl.1 ) A433 - A433 2020年4月

肝疾患における移行期医療小児NAFLD患者の背景疾患と移行医療への課題

上村博輝, 上村顕也, 寺井崇二

肝臓 61 ( Suppl.1 ) A142 - A142 2020年4月

肝移植医療における内科・外科連携の現状と問題点本県における急性肝不全に対する肝移植再開に向けた診療ネットワーク運用の検討

薛徹, 寺井崇二

肝臓 61 ( Suppl.1 ) A125 - A125 2020年4月

門脈圧亢進症の診断と治療原発性胆汁性胆管炎における食道静脈瘤発生の検討

薛徹, 横山純二, 寺井崇二

肝臓 61 ( Suppl.1 ) A151 - A151 2020年4月

NAFLDの病態解明及び新規治療法の探索非アルコール性脂肪性肝炎(NASH)モデルマウスを用いたスフィンゴシン1リン酸受容体ブロックによる脂質構成の変化と発癌機構の解明

吉田智彰, 土屋淳紀, 寺井崇二

肝臓 61 ( Suppl.1 ) A215 - A215 2020年4月

肝硬変の予後改善を目指した治療戦略肝硬変に対する間葉系幹細胞由来のエクソソーム療法の開発に向けて

土屋淳紀, 竹内卓, 寺井崇二

肝臓 61 ( Suppl.1 ) A92 - A92 2020年4月

生体試料を用いた研究の最前線間葉系幹細胞のエクソソームによる肝線維化改善抗炎症性マクロファージ誘導法の開発

竹内卓, 土屋淳紀, 寺井崇二

肝臓 61 ( Suppl.1 ) A33 - A33 2020年4月

　前のページ - 次のページ　

<寺井 崇二>

論文 - 寺井 崇二

<寺井　崇二>

論文 - 寺井　崇二